CN101525336A - Carbapenem compound containing substituted formohydrazide group - Google Patents
Carbapenem compound containing substituted formohydrazide group Download PDFInfo
- Publication number
- CN101525336A CN101525336A CN200810127466A CN200810127466A CN101525336A CN 101525336 A CN101525336 A CN 101525336A CN 200810127466 A CN200810127466 A CN 200810127466A CN 200810127466 A CN200810127466 A CN 200810127466A CN 101525336 A CN101525336 A CN 101525336A
- Authority
- CN
- China
- Prior art keywords
- methyl
- ester
- group
- hydrate
- formyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medical technologies, and more particularly relates to a carbapenem compound containing a substituted formohydrazide group as shown in the general formula (I), and pharmaceutically acceptable salt, easily-hydrolytic ester, isomer, hydrate and the hydrates of the ester or the salt thereof, wherein R<1>, R<2>, R<3>, R<4>, R<5> and R<6> are as defined in the specification. The invention also relates to a preparation method of the compound, pharmaceutical composition containing the compound, and the application of the compound in preparing a drug for treating or preventing infectious diseases.
Description
1, technical field
The invention belongs to medical technical field, be specifically related to the hydrate of ester, its isomer, its hydrate and ester or salt of carbapenem compounds, its pharmacy acceptable salt, its facile hydrolysis of the new formohydrazide group that contains replacement, the preparation method of these compounds, the pharmaceutical composition that contains these compounds, and these compounds are in the purposes that is used for preparing the medicine that treats and/or prevents infectious diseases.
2, background technology
Carbapenem antibiotic is the class β-Nei Xiananleikangshengsu that the seventies grows up.Because of its has a broad antifungal spectrum, anti-microbial activity is strong, and stable to β-Nei Xiananmei, and receives much concern.Its constructional feature is, the sulphur that the penam parent nucleus is 1 is replaced by carbon, and 2 have two keys, the effect of the five-ring of compound penicillin and the conjugated double bond activation beta-lactam nucleus of cynnematin; 6 hydroxyethyl side chains are transoid conformation.
This similar drug that has gone on the market at present has imipenum, meropenem, S-4661, biapenem, ertapenem etc.Because antibiotic abuse causes the continuous increase of bacterial drug resistance, and because the limitation that digestive tube absorbs, the carbapenems of listing clinically can only be as the injection administration at present, clinical availability is not high, and except that ertapenem the transformation period all shorter, can not meet clinical needs.
Therefore, be badly in need of research and development and have better antibacterial activity, and have the long-acting carbapenem antibiotic of good chemical stability and DHP-I stability.
3, summary of the invention
Technical scheme of the present invention is as follows:
The invention provides the hydrate of ester, its isomer, its hydrate and the ester or the salt of the compound shown in the general formula (I), its pharmacy acceptable salt, its facile hydrolysis:
Wherein, R
1Represent hydrogen atom or carboxyl-protecting group;
R
2Represent hydrogen atom or amino protecting group;
R
3Representative is replaced by one or more substituting groups or unsubstituted following group:
Described substituting group is selected from halogen atom, hydroxyl, carboxyl, amino, nitro, cyano group, replaced or unsubstituted sulfonamido by low alkyl group, by halogen atom, hydroxyl, carboxyl, amino, nitro or cyano group replaces or unsubstituted low alkyl group, lower alkoxy;
R
4, R
5, R
6Independently represent hydrogen atom or low alkyl group respectively.
Preferred compound is:
Wherein, R
1Represent hydrogen atom or carboxyl-protecting group,
Described carboxyl-protecting group is selected from methyl, ethyl, the tertiary butyl, methoxymethyl, first thiomethyl, benzyloxymethyl, phenacyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R
2Represent hydrogen atom or amino protecting group,
Described amino protecting group is selected from methyl, ethyl, the tertiary butyl, benzyl, formyl radical, ethanoyl, allyloxy carbonyl, phenacyl, tert-butoxycarbonyl, to the nitro benzyloxycarbonyl, to methoxyl group benzyloxy base carbonyl, 3-acetoxyl group propyl group or diazo;
R
3Representative is replaced by one or more substituting groups or unsubstituted following group:
Described substituting group is selected from halogen atom, and carboxyl is replaced or unsubstituted sulfonamido by low alkyl group, by halogen atom, hydroxyl, carboxyl, amino replacement or unsubstituted low alkyl group, lower alkoxy;
R
4, R
5, R
6Independently represent hydrogen atom, methyl, ethyl or propyl group respectively.
Further preferred compound is:
Wherein, R
1Represent hydrogen atom or carboxyl-protecting group,
Described carboxyl-protecting group is selected from methyl, the tertiary butyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R
2Represent hydrogen atom or amino protecting group,
Described amino protecting group is selected from methyl, the tertiary butyl, formyl radical, allyloxy carbonyl, tertbutyloxycarbonyl, to the nitro benzyloxycarbonyl, to methoxyl group benzyloxy base carbonyl or diazo;
R
3Representative is replaced by one or more substituting groups or unsubstituted following group:
Described substituting group is selected from fluorine atom, chlorine atom, carboxyl, sulfonamido, the low alkyl group, the lower alkoxy that are replaced by halogen atom;
R
4, R
5, R
6Independently represent hydrogen atom or methyl respectively.
Table 1 part of compounds of the present invention
" halogen atom " of the present invention is fluorine atom, chlorine atom, bromine atoms or iodine atom.
" low alkyl group " of the present invention is C
1-6The alkyl of straight or branched is as methyl, ethyl, propyl group, sec.-propyl, butyl, isobutyl-, the tertiary butyl, sec-butyl, amyl group, neo-pentyl, hexyl etc.
" amino protecting group " of the present invention refers to that routine is used for the blocking group of substituted-amino acid proton, this type of examples of groups comprises: methyl, ethyl, encircle third methyl, 1-methyl isophthalic acid-ring third methyl, the diisopropyl methyl, the 9-fluorene methyl, 9-(2-sulfo-) fluorene methyl, furfuryl, 2,2, the 2-trichloromethyl, the 2-halogenated methyl, 2-iodine ethyl, 2-trimethyl silyl ethyl, 2-methylmercaptoethyl, 2-methylsulfonyl ethyl, 2-(p-toluenesulfonyl) ethyl, 2-phosphorus base ethyl, 1,1-dimethyl-3-(N, N-dimethylformamide base) propyl group, 1,1-phenylbenzene-3-(N, the N-diethylin) propyl group, 1-methyl isophthalic acid-(adamantyl) ethyl, 1-methyl isophthalic acid-styroyl, 1-methyl isophthalic acid-(3, the 5-dimethoxy phenyl) ethyl, 1-methyl isophthalic acid-(4-xenyl) ethyl, 1-methyl isophthalic acid-(to the phenylazo-phenyl) ethyl, 1,1-dimethyl-2,2,2-three chloroethyls, 1,1-dimethyl-2-cyanoethyl, isobutyl-, the tertiary butyl, tert-pentyl, cyclobutyl, 1-methyl cyclobutyl, cyclopentyl, cyclohexyl, the 1-methylcyclohexyl, the 1-adamantyl, isobornyl, vinyl, allyl group, cinnamyl, phenyl, 2,4,6-tri-tert phenyl, the m-nitro base, the S-phenyl, the 8-quinolyl, N '-hydroxy piperidine base, 4-(1,4-lupetidine base), 4,5-phenylbenzene-3-oxazoline-2-ketone, benzyl, 2,4, the 6-trimethyl benzyl, to methoxy-benzyl, to methoxyl group benzyloxy base carbonyl, 3, the 5-dimethoxy-benzyl, to oxy-benzyl in the last of the ten Heavenly stems, to nitrobenzyl, to the nitro benzyloxycarbonyl, adjacent nitrobenzyl, 3,4-dimethoxy-6-nitrobenzyl, to bromobenzyl, the benzyl chloride base, 2, the 4-dichloro benzyl, to the cyano group benzyl, adjacent (N, N-dimethylformamide base) benzyl, between-chloro-is right-the acyloxy benzyl, to (dihydroxyl boryl) benzyl, to (phenylazo-) benzyl, to (to the anisole azo-group) benzyl, 5-benzoisoxazole ylmethyl, 9-anthryl methyl, diphenyl-methyl, phenyl (ortho-nitrophenyl base) methyl, two (2-pyridyl) methyl, 1-methyl isophthalic acid-(4-pyridyl) ethyl, the isonicotine base, the S-benzyl, the fixed basic carbonyl of N '-piperazine, the carbamate of N '-p-toluenesulfonyl aminocarboxyl and N '-phenylamino thiocarbonyl; Formyl radical, ethanoyl, ethanoyl-pyridine, (N '-the dithio benzyloxycarbonyl amino) ethanoyl, 3-phenyl propionyl, 3-(to hydroxyphenyl) propionyl, 3-(ortho-nitrophenyl base) propionyl, 2-methyl-2-(ortho-nitrophenyl oxygen base) propionyl, 2-methyl-2-(adjacent phenylazo-phenoxy group) propionyl, 4-chloro butyryl radicals, isobutyryl, adjacent nitro cinnamoyl, the pyridine formyl radical, N '-acetyl methionyl, N '-benzoyl-phenylalkyl, benzoyl, to the phenyl benzoyl, to anisoyl, o-nitrobenzoyl, the acid amides of adjacent (benzoyloxy methyl) benzoyl and right-P-benzoyl; Phthaloyl, 2, the inferior acid amides of the ring of 3-phenylbenzene maleoyl and dithio succinyl; Tert-butoxycarbonyl; allyl group; allyloxy carbonyl; phenacyl; 3-acetoxyl group propyl group; 4-nitro-1-cyclohexyl-2-oxo-3-tetramethyleneimine-3-base; quaternary ammonium salt; methoxymethyl; 2-chloroethoxy methyl; benzyloxymethyl; the valeryl methyl; [1-(alkoxycarbonyl amido)]-2; 2; 2; trifluoroethyl; [1-Trifluoromethyl-1-(to the chlorophenoxy methoxyl group) 2; 2; 2;-trifluoro] ethyl; the 2-THP trtrahydropyranyl; 2; the 4-dinitrophenyl; benzyl; 3; the 4-dimethoxy-benzyl; adjacent nitrobenzyl; two (p-methoxyphenyl) methyl; trityl; (p-methoxyphenyl) diphenyl methyl; phenylbenzene-4-pyridylmethyl; 2-picolyl-N '-oxide compound; 5-two phenylpropyl alcohol suberane bases; N '; N '-dimethylaminomethylene; N '-isopropylidene; benzylidene; to the methoxyl group benzylidene; to the nitro benzylidene; salicylidene; 5-chlorine salicylidene; diphenylmethylene; (5-chloro-2-hydroxyphenyl) phenylmethylene; (acyl group vinyl); 5; 6-dimethyl-3-oxo-1-cyclohexenyl; borine; [phenyl (pentacarbonyl chromium or tungsten)] carbonyl; copper or chelates of zinc; nitro; nitroso-group; oxide compound; diphenylphosphino; diformazan sulfenyl phosphinyl; hexichol sulfenyl phosphinyl; the diethyl phosphoryl; the dibenzyl phosphoryl; the diphenylphosphine acyl group; phosphoryl; trimethyl silyl; thiophenyl; the ortho-nitrophenyl sulfenyl; 2; 4-dinitrobenzene sulfenyl; 2-nitro-4-anisole sulfenyl; three benzylthios; benzenesulfonyl; to the anisole alkylsulfonyl; 2; 4,6-Three methyl Benzene alkylsulfonyl; methyl sulphonyl; the benzene methylsulfonyl; to the toluene methylsulfonyl; trifluoromethyl sulfonyl; the phenacyl alkylsulfonyl; diazo etc.
" carboxyl-protecting group " of the present invention refers to that routine is used for the blocking group of substituted carboxylic acid acid proton.This examples of groups comprises: methoxymethyl, the first thiomethyl, THP trtrahydropyranyl, tetrahydrofuran base, the methoxyethyl methyl, benzyloxymethyl, phenacyl, allyl group, to bromobenzene formyl methyl, the Alpha-Methyl phenacyl, to the methoxybenzoyl methyl, the diacyl methyl, the N-phthalimidomethyl, methyl, ethyl, diphenyl methyl, 2,2,2-three chloroethyls, the 2-halogenated ethyl, ω-chloro alkyl, 2-(trimethyl silyl) ethyl, 2-methylmercaptoethyl, 2-(p-nitrophenyl sulfenyl) ethyl, 2-(to the toluene sulfenyl) ethyl, 1-methyl isophthalic acid-styroyl, the tertiary butyl, cyclopentyl, cyclohexyl, two (ortho-nitrophenyl base) methyl, 9-fluorenyl methyl, 2-(9, the 10-dioxo) fluorenyl methyl, 5-hexichol sulfenyl, benzyl, 2,4, the 6-trimethyl benzyl, to bromobenzyl, adjacent nitrobenzyl, to nitrobenzyl, to methoxy-benzyl, piperonyl, the 4-picolyl, trimethyl silyl, triethylsilyl, t-butyldimethylsilyl, the sec.-propyl dimetylsilyl, the phenyl dimetylsilyl, the S-tertiary butyl, the S-phenyl, the S-2-pyridyl, N-hydroxy piperidine base, N-hydroxyl succinimido, N-hydroxyl phthaloyl imino, N-hydroxybenzotriazole base, O-acyl group oxime, 2,4-dinitrobenzene sulfenyl, 2-alkyl-1, the 3-oxazoline, 4-alkyl-5-oxo-1, the 3-oxazolidine, 5-alkyl-4-oxo-1, the 3-diox, the triethyl stannane, tri-n-butyl stannane; N, N '-di-isopropyl hydrazides etc.
Further preferred compound is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 1, structural formula is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (3-carboxyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 2, structural formula is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 3, structural formula is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 4, structural formula is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 5, structural formula is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 6, structural formula is as follows:
Chemical name: (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, hereinafter to be referred as compound 7, structural formula is as follows:
The present invention also provides the preparation method of above-claimed cpd:
The preparation method one
Reaction equation:
Reactions steps:
The preparation of step 1 compound (I)
In the exsiccant reaction flask, add (2S, 4S)-4-acetylthio-2-carboxyl-tetramethyleneimine (being raw material 1), anhydrous tetrahydro furan.Under nitrogen protection, add 1 in room temperature, 1-carbonyl dimidazoles (being CDI), reaction, the tetrahydrofuran solution adding raw material 2 below 0 ℃ continues reaction.Drip 1mol/L hydrochloric acid then, with ethyl acetate extraction, organic phase is water, saturated nacl aqueous solution washing successively, and concentrating under reduced pressure, solid get compound (I) with the ethanolic soln recrystallization.
The preparation of step 2 compound (II)
The dichloromethane solution that adds compound (I) in reaction flask, the ice bath cooling adds triethylamine, stirs the back and drips (Boc)
2The dichloromethane solution of O stirs.Add entry under the frozen water cooling, divide water-yielding stratum, water layer is used dichloromethane extraction again, merges organic layer, anhydrous sodium sulfate drying, be concentrated into driedly, resistates adds the hydrochloric acid of 3mol/L, stirs, and is adjusted to alkalescence with dilute alkaline soln, separate out solid, solid gets compound (II) with the acetone soln recrystallization.
The preparation of step 3 compound (III)
In the dry reaction bottle, add the acetonitrile solution of raw material 3, cooling, the acetonitrile solution of adding diisopropylethylamine and compound (II), 0 ℃ of stirring.After reaction finishes, add the ethyl acetate dilution, water, saturated salt washing successively, organic layer drying, concentrated gets compound (III).
The preparation of step 4 compound (IV)
(III) dissolves in the methylene dichloride with compound, adds methyl-phenoxide and Nitromethane 99Min., drips the Nitromethane 99Min. solution of 1mol/L aluminum chloride down in low temperature, stir, add entry, separate out solid, filter, filter cake is dissolved in the mixed solution of THF and water, adds 10% palladium-charcoal, stirring reaction under the room temperature 5MPa hydrogen pressure, filtering palladium charcoal, add THF in the filtrate, water layer is collected in layering.In THF, add 5% magnesium chloride brine again, leave standstill, divide water-yielding stratum, repetitive operation.Water merges, and 0 ℃ slowly splashes into methyl alcohol, stirs, and filters, and the filter cake recrystallization gets compound (IV).
The preparation method two:
Reaction equation
Reactions steps:
The preparation of step 1 compound (I)
Add raw material 1 in the exsiccant reaction flask, anhydrous tetrahydro furan under nitrogen protection, adds DCC (dicyclohexyl carbimide) in room temperature, and reaction is adding raw material 2 in batches below 10 ℃, continue reaction.With hydrochloric acid soln, water, the saturated nacl aqueous solution washing of 1N, concentrating under reduced pressure, solid get compound (I) with methyl alcohol-ethyl acetate solution recrystallization to organic phase successively.
The preparation of step 2 compound (II)
In reaction flask, add compound (I), hydrochloric acid-methanol solution of 10%, the temperature rising reflux stirring reaction adds entry under the frozen water cooling, divides water-yielding stratum, water layer is used dichloromethane extraction again, merge organic layer, anhydrous sodium sulfate drying, be concentrated into driedly, be adjusted to neutrality with dilute alkaline soln, separate out solid, get compound (II).
The preparation of step 3 compound (III)
In the dry reaction bottle, add the acetonitrile solution of raw material 3, cooling, the acetonitrile solution of adding diisopropylethylamine and intermediate 2, stir, after reaction finishes, add the ethyl acetate dilution, water, saturated salt washing successively, organic layer drying, concentrated gets compound (III).
The preparation of step 4 compound (IV)
(III) is dissolved in the mixed solution of THF and water with compound, adds 10% Lin Dela palladium-charcoal, stirring reaction under the room temperature 5MPa hydrogen pressure, and filtering palladium charcoal removes tetrahydrofuran (THF) under reduced pressure, and residual solution is washed 1 time with ethyl acetate.Water layer slowly splashes into ethanol in 0 ℃, stirs, filter, compound (IV).
R in the above reaction equation
3, R
4, R
5, R
6The representative group as mentioned before, the carboxyl on the compound (IV) can be protected by carboxyl-protecting group, the hydrogen atom on the nitrogen-atoms can be protected by amino protecting group, is compound shown in the general formula (I).
The above-mentioned arbitrary compound pharmacy acceptable salt of the present invention is organic acid salt, inorganic acid salt, organic alkali salt or inorganic base salts, and wherein organic acid comprises acetate, trifluoroacetic acid, methylsulfonic acid, toluenesulphonic acids, toxilic acid, succsinic acid, tartrate, citric acid, fumaric acid; Mineral acid comprises hydrochloric acid, Hydrogen bromide, nitric acid, sulfuric acid, phosphoric acid; Organic bases comprises meglumine, glucosamine; Mineral alkali comprises the basic cpd of sodium, potassium, barium, calcium, magnesium, zinc, lithium.
The ester that the claimed compound of the present invention is easy to hydrolysis is the compound that its carboxyl exists with the ester group form that is easy to hydrolysis.These esters can be conventional, lower alkane acyloxyalkyl group ester for example, acetoxyl methyl ester, pivalyl oxygen methyl ester, 1-acetoxyl ethyl ester, 1-pivalyl oxygen ethyl ester; Lower alkoxycarbonyl oxyalkyl ester, methoxycarbonyl oxygen methyl ester, 1-ethoxycarbonyl-oxygen ethyl ester, the different third oxygen ketonic oxygen ethyl ester of 1-; The lactone group ester, cumarone ketone group ester, sulfo-benzo furanonyl ester; The lower alkoxy methyl ester, methoxymethyl ester; Lower alkane acyl amino methyl ester, the acetylamino methyl ester.The ester that also can use other is for example: benzyl ester and cyano methyl ester.Other examples of these esters are as follows: (2,2-dimethyl-1-oxygen propoxy-) methyl ester; (1RS)-1-acetoxyl group ethyl ester; 2-[(2-methyl propoxy-) carbonyl]-the pentenyl ester; The 1-[[(1-methyl ethoxy) carbonyl] oxygen] ethyl ester; 1-(acetoxyl) ethyl ester; (5-methyl-2-oxo-1,3-dioxole-4-yl) methyl ester; The 1-[[(cyclohexyloxy) carbonyl] oxygen] ethyl ester; 3,3-dimethyl-2-oxo butyl ester.It is evident that for the professional of this area the ester that is easy to hydrolysis of The compounds of this invention can form at the free carboxy place of this compound.
Isomer of the present invention is meant its all differences to stereoisomerism, diastereo-isomerism and tautomeric form.When a key was represented with a wedge, this showed that this key will come out from paper on three-dimensional, and when a key was shade, this showed that this key will return in the paper on three-dimensional.Formula (I) compound has many three-dimensional centers, that is: on the 4-position, on the 5-position, on the 6-position.
The ester of the compound shown in the general formula (I), its pharmacy acceptable salt, its facile hydrolysis, its isomer can be hydrate forms.Hydration can be finished in preparation process or can be utilized the water absorbability of original anhydrous product to carry out gradually.
The present invention includes the hydrate of ester, its isomer, its hydrate and the ester or the salt of arbitrary compound recited above, its pharmacy acceptable salt, its facile hydrolysis, with the pharmaceutical composition of other active pharmaceutical ingredients, as cilastatin and sodium salt thereof, Betamipron.
The present invention is the claimed hydrate that comprises ester, its isomer, its hydrate and the ester or the salt of arbitrary compound recited above, its pharmacy acceptable salt, its facile hydrolysis further; pharmaceutical composition with one or more pharmaceutical carriers and/or thinner; for clinically or pharmaceutically acceptable arbitrary formulation, be preferably oral preparations or injection.Wherein contain the compound 0.05g～5g shown in the general formula (I) of physiology significant quantity, can be 0.05g, 0.1g, 0.125g, 0.2g, 0.25g, 0.3g, 0.4g, 0.5g, 0.6g, 0.75g, 1g, 1.25g, 1.5g, 1.75g, 2g, 2.5g, 3g, 4g, 5g etc.
The hydrate of the ester of The compounds of this invention, its pharmacy acceptable salt, its facile hydrolysis, its isomer, its hydrate and ester or salt, can be oral or mode such as administered parenterally be applied to the patient who needs this treatment.
When being used for administered parenterally, can be made into injection.Injection means the intravital solution of confession injection, emulsion or the suspension that medicine is made and supplies to face with preceding preparation or be diluted to solution or the sterile preparation of the powder of suspension or strong solution that injection can be divided into injection liquid, injectable sterile powder and concentrated solution for injection.Injection liquid means that the confession that medicine is made is injected into sterile solution type injection liquid, emulsion-type injection liquid or the suspension type injection liquid of using in the body, can be used for intramuscularly, intravenous injection, intravenous drip etc.; Its specification has 1ml, 2ml, 5ml, 10ml, 20ml, 50ml, 100ml, 200ml, 250ml, 500ml etc., and wherein large volume (generally the being not less than 100ml) injection liquid of using for intravenous drip also claims intravenous infusion.Injectable sterile powder means that confession that medicine is made is faced with the suitable sterile solution of preceding usefulness and is mixed with settled solution or the evenly sterilized powder or the aseptic block of suspension, available suitable solvent for injection preparation back injection, also available intravenous infusion preparation posterior vein instils; Sterilized powder makes with solvent crystallization, spray-drying process or freeze-drying etc.Concentrated solution for injection means that confession that medicine is made faces the aseptic strong solution of using for intravenous drip with preceding dilution.
When making injection, can adopt the ordinary method production in the existing pharmacy field, optional use solvent or non-aqueous solvent.The most frequently used aqueous solvent is a water for injection, also available 0.9% sodium chloride solution or other suitable aqueous solution; Non-aqueous solvent commonly used is a vegetables oil, is mainly the injection soybean oil, and other also have the aqueous solution of ethanol, propylene glycol, polyoxyethylene glycol etc.During the preparation injection, can not add additives, also can add suitable additives, as osmotic pressure regulator, pH value conditioning agent, solubilizing agent, weighting agent, oxidation inhibitor, fungistat, emulsifying agent, suspending agent etc. according to the character of medicine.Osmotic pressure regulator commonly used comprises sodium-chlor, glucose, Repone K, magnesium chloride, calcium chloride, sorbyl alcohol etc., preferred sodium-chlor or glucose; PH value conditioning agent commonly used comprises acetic acid-sodium-acetate, lactic acid, Citric Acid-Sodium Citrate, sodium bicarbonate-yellow soda ash etc.; Solubilizing agent commonly used comprises Polysorbate 80, propylene glycol, Yelkin TTS, polyoxyethylenated castor oil etc.; Weighting agent commonly used comprises lactose, N.F,USP MANNITOL, sorbyl alcohol, dextran etc.; Oxidation inhibitor commonly used has S-WAT, sodium bisulfite, Sodium Pyrosulfite etc.; Fungistat commonly used is phenol, cresols, trichloro-butyl alcohol etc.Injection container commonly used has glass ampoule, vial, plastic ampoule, Plastic Bottle etc.
Be used for when oral, can be made into conventional solid preparation, as tablet, capsule, pill, granule etc.; Also can be made into oral liquid, as oral solution, oral suspensions, syrup etc.Tablet means disk shape or the special-shaped flaky solid preparation that medicine and the auxiliary materials and mixing compacting that suits form, based on oral ordinary tablet, other has lozenge, Sublingual tablet, mouth paster, chewable tablet, dispersible tablet, fuse, effervescent tablet, slow releasing tablet, controlled release tablet and enteric coated tablet etc.Capsule means medicine or is added with the auxiliary material filling in Capsules or be sealed in solid preparation in the soft capsule material, according to its dissolving and release characteristics, can be divided into hard capsule (being commonly referred to as capsule), soft capsule (capsule and pill), slow releasing capsule, controlled release capsule and enteric coated capsule etc.Pill means medicine and suitable auxiliary material uniform mixing, and the spherical or near-spherical solid preparation so that proper method is made comprises dripping pill, sugar-pill, piller etc.Granule means that medicine and suitable auxiliary material make the dried particles shape preparation with certain particle size, can be divided into soluble particles (being commonly referred to as particle), mix suspension grain, effervescent granule, enteric coated particles, slow-releasing granules and controlled release granule etc.Oral solution means that medicine dissolution makes for oral clarified liq preparation in suitable solvent.Oral suspensions means the insoluble solid pharmaceutical, is dispersed in the liquid medium, makes for oral suspension body preparation, also comprises dry suspensoid or dense suspension.Syrup means the dense aqueous sucrose solution that contains medicine.
When making oral preparations, can add suitable weighting agent, tackiness agent, disintegrating agent, lubricant etc.Weighting agent commonly used comprises starch, Icing Sugar, calcium phosphate, calcium sulfate two water things, dextrin, Microcrystalline Cellulose, lactose, pregelatinized Starch, N.F,USP MANNITOL etc.; Typical binders comprises Xylo-Mucine, PVP-K30, hydroxypropylcellulose, starch slurry, methylcellulose gum, ethyl cellulose, hypromellose, gelling starch etc.; Disintegrating agent commonly used comprises dry starch, polyvinylpolypyrrolidone, croscarmellose sodium, sodium starch glycolate, low-substituted hydroxypropyl cellulose etc.; Conventional lubricants comprises Magnesium Stearate, talcum powder, sodium lauryl sulphate, micropowder silica gel etc.
Usually, have been found that carbapenems is nontoxic to warm-blooded animal, and this general rule also is applicable to The compounds of this invention.With preferred compound of the present invention can prevent the needed excessive dosage of infectation of bacteria, not to be noted by caused tangible poisoning aura of The compounds of this invention or side effect to the mouse administration.
The carbapenem compounds that the present invention also provides the formohydrazide group that contains replacement preparation be used for the treatment of and/or the medicine of prophylaxis against infection diseases in purposes.The new carbapenem antibiotic of the present invention all has better antibacterial activity to Gram-positive and negative, aerobic and anerobe and hospital clinical pathogenic bacteria, can be used for treating and/or preventing the various diseases that causes by pathogenic micro-organism, as respiratory tract infection and urinary tract infection.
The carbapenem compounds of the formohydrazide group that contains replacement of the present invention compared with prior art has the following advantages:
(1) The compounds of this invention has good anti-microbial activity and shows hypotoxicity, can being used for the treatment of and/or preventing various Mammalss (comprising the mankind) by the caused various diseases of sensitive organism by safety;
(2) The compounds of this invention has a broad antifungal spectrum, Gram-positive and negative, aerobic and anerobe and hospital clinical pathogenic bacteria all there is better antibacterial activity, especially the resistance pseudomonas aeruginosa there is better antibacterial activity, and MRSA is had certain activity;
(3) The compounds of this invention has high stability to β-Nei Xiananmei and DHP-I, can be used for β-Nei Xiananmei and produces bacterium, and do not need to share with other medicines;
(4) long half time in the The compounds of this invention body can reduce administration number of times, improves patient's tolerance;
(5) The compounds of this invention preparation technology is simple, and medicine purity height, yield height, steady quality are easy to carry out large-scale commercial production.
Below further set forth the beneficial effect of the carbapenem compounds of the formohydrazide group that contains replacement of the present invention by in-vitro antibacterial experiment, but this should be interpreted as that the southern antibiotics of training of the present invention only has following beneficial effect.
The antibacterial activity in vitro of experimental example The compounds of this invention
For trying bacterial classification: following is the clinical isolates strain, all buys in public institution
Gram positive organism: MSSA (MSSA), methicillin-resistant staphylococcus aureus (MRSA), methicillin-sensitivity staphylococcus epidermidis (MSSE), methicillin-resistant staphylococcus epidermidis (MRSE), the responsive streptococcus pneumoniae (PSSP) of penicillin, penicillin resistance streptococcus pneumoniae (PRSP), streptococcus pyogenes, enterococcus faecalis;
Gram-negative bacteria: hemophilus influenzae, escherichia coli, klebsiella pneumoniae, Proteus mirabilis, enterobacter cloacae, Pseudomonas aeruginosa; Grain-negative anerobe: bacteroides fragilis.
Trial-product: The compounds of this invention 1-7, self-control, chemical name and structural formula are as mentioned before;
Imipenum: commercial; Meropenem: commercial.
Experimental technique: agar dilution, with reference to " pharmacological testing methodology " P1659-1660, People's Health Publisher, chief editor: Xu Shuyun etc., release: the 1st edition the 3rd edition the 5th printing January in 2002 in August nineteen eighty-two.
Experimental result and conclusion:
Table 2 The compounds of this invention is to the anti-microbial activity of clinical separation gram positive organism
By table 2 experimental result as seen, compare with meropenem with imipenum, The compounds of this invention 1-7 all has the excellent antibiotic activity to the clinical isolating examination gram positive organism that supplies.
Table 3 The compounds of this invention is to the anti-microbial activity of clinical separation gram-negative bacteria
By table 3 experimental result as seen, compare with meropenem with imipenum, The compounds of this invention 1-7 comprises that to clinical isolating for the examination gram-negative bacteria Grain-negative anerobe has the excellent antibiotic activity.
Above-mentioned experimental result shows, The compounds of this invention all has potent anti-microbial effect to gram positive organism, negative bacterium and resistant organism thereof and anerobe, compares with immediate prior art, and anti-microbial activity quite or better, and has a broad antifungal spectrum has the good clinical application potential.
4, embodiment
The embodiment of form is described in further detail foregoing of the present invention by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following examples.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.The auxiliary material of each formulation can be replaced with acceptable accessories in following examples, perhaps reduces, increases.
Embodiment 1 (2S, 4S)-preparation of 4-acetylthio-2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-1-tetramethyleneimine
In the exsiccant reaction flask, add (2S, 4S)-4-acetylthio-2-carboxyl-tetramethyleneimine 14.5g (50mmol), anhydrous tetrahydro furan 150ml.Under nitrogen protection, add 1 in room temperature, 1-carbonyl dimidazoles 13g (80mmol), reaction 0.5h at the tetrahydrofuran solution 100ml that adds 11.2g3-diazanyl-1-benzsulfamide (60mmol) below 0 ℃, continues reaction 0.5h.Drip 1mol/L hydrochloric acid 60ml then, extract with ethyl acetate (100ml * 2), organic phase is water, saturated nacl aqueous solution washing successively, and concentrating under reduced pressure, solid get solid 14.1g, yield: 78.7% with the ethanolic soln recrystallization.
Embodiment 2 (2S, 4S)-preparation of 4-acetylthio-2-formyl (3-carboxyl-benzene-1-yl) diazanyl-tetramethyleneimine
Concrete preparation method's reference example 1.Throw (2S, 4S)-4-acetylthio-2-carboxyl-tetramethyleneimine 14.5g (50mmol), 3-diazanyl-1-phenylformic acid 9.1g (60mmol).Get product 11.3g, yield: 69.6%.
Embodiment 3 (2S, 4S)-preparation of 4-acetylthio-2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine
Concrete preparation method's reference example 1.Throw (2S, 4S)-4-acetylthio-2-carboxyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 14.5g (50mmol), 2-Trifluoromethyl-1-phenyl hydrazine 10.7g (60mmol).Get product 14.5g, yield: 83.6%.
Embodiment 4 (2S, 4S)-preparation of 4-acetylthio-2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine
Concrete preparation method's reference example 1.Throw (2S, 4S)-4-acetylthio-2-carboxyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 14.5g (50mmol), 2-chloro-5-Trifluoromethyl-1-phenyl hydrazine 12.6g (60mmol).Get product 14.8g, yield: 77.3%.
Embodiment 5 (2S, 4S)-preparation of 4-acetylthio-2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-tetramethyleneimine
Concrete preparation method's reference example 1.Throw (2S, 4S)-4-acetylthio-2-carboxyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 14.5g (50mmol), 1-(benzo [d] thiazol-2-yl) hydrazine 9.9g (60mmol).Get product 13.7g, yield: 81.5%.
Embodiment 6 (2S, 4S)-preparation of 4-sulfydryl-2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine
In reaction flask, add (2S, 4S)-the dichloromethane solution 100ml of 4-acetylthio-2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-tetramethyleneimine 10.8g (30mmol), ice bath is chilled under 5 ℃, adds triethylamine 12ml, stirs the back and drips 15g (Boc)
2The dichloromethane solution 100ml of O stirs 1h.The frozen water cooling adds 100ml water down, divide water-yielding stratum, water layer is used the dichloromethane extraction of 50ml * 3 again, merges organic layer, anhydrous sodium sulfate drying, be concentrated into dried, resistates adds the hydrochloric acid 100ml of 3mol/L, stirs 2h, is adjusted to alkalescence with dilute alkaline soln, separate out solid, solid gets product 11.2g, yield: 89.9% with the acetone soln recrystallization.
Embodiment 7 (2S, 4S)-preparation of 4-sulfydryl-2-formyl (3-carboxyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine
Concrete preparation method's reference example 6.Throw (2S, 4S)-4-acetylthio-2-formyl (3-carboxyl-benzene-1-yl) diazanyl-tetramethyleneimine 9.7g (30mmol).Get product 8.9g, yield: 77.6%.
Embodiment 8 (2S, 4S)-preparation of 4-sulfydryl-2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine
Concrete preparation method's reference example 6.Throw (2S, 4S)-4-sulfydryl-2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine 10.4g (30mmol).Get product 9.8g, yield: 80.5%.
Embodiment 9 (2S, 4S)-4-sulfydryl-2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine
Preparation
Concrete preparation method's reference example 6.Throw (2S, 4S)-4-acetylthio-2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine 11.5g (30mmol).Get product 10.0g, yield: 75.8%.
Embodiment 10 (2S, 4S)-system of 4-sulfydryl-2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine
Be equipped with
Concrete preparation method's reference example 6.Throw (2S, 4S)-4-acetylthio-2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-tetramethyleneimine 10.1g (30mmol).Get product 9.6g, yield: 81.3%.
Embodiment 11 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine
-4-yl] sulfenyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy's system
Be equipped with
In the dry reaction bottle, add (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-1-hydroxyethyl]-the acetonitrile solution 120ml of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 11.9g (20mmol), be chilled to below-10 ℃, add diisopropylethylamine 5ml and (2S, 4S)-the acetonitrile solution 80ml of 4-sulfydryl-2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 8.7g (21mmol), 0 ℃ is stirred 15h.After reaction finishes, add ethyl acetate 300ml dilution, water, saturated salt washing successively, organic layer drying, concentrated gets solid 12.3g, yield: 74.1%.
Embodiment 12 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl (3-carboxyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-
Base] sulfenyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy's preparation
Concrete preparation method's reference example 11.Throw (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 11.9g (20mmol), (2S, 4S)-4-sulfydryl-2-formyl (3-carboxyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 8.0g (21mmol).Get product 10.1g, yield: 69.3%.
Embodiment 13 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) pyrroles
Alkane-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy
Preparation
Concrete preparation method's reference example 11.Throw (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 11.9g (20mmol), (2S, 4S)-4-sulfydryl-2-formyl (3-carboxyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 8.5g (21mmol).Get product 11.1g, yield: 73.9%.
Embodiment 14 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl)
Tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid is to nitrobenzyl
The preparation of ester
Concrete preparation method's reference example 11.Throw (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 11.9g (20mmol), (2S, 4S)-4-sulfydryl-2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 9.2g (21mmol).Get product 11g, yield: 70.3%.
Embodiment 15 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [1-(benzo [d] thiazole 2-yl)] diazanyl-1-(tertbutyloxycarbonyl) pyrroles
Alkane-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy
Preparation
Concrete preparation method's reference example 11.Throw (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 11.9g (20mmol), (2S, 4S)-4-sulfydryl-2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine 8.3g (21mmol).Get product 11.4g, yield: 72.8%.
Embodiment 16 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl
-6-[(1R)-the 1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid (compound 1)
With (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 7.6g (10mmol) is dissolved in the 50ml methylene dichloride, add methyl-phenoxide 10ml and Nitromethane 99Min. 20ml, in-50 ℃ of Nitromethane 99Min. solution 100ml that drip the 1mol/L aluminum chloride down ,-40 ℃ are stirred 2h, add entry 200ml, separate out solid, filter, filter cake is dissolved in the mixed solution of 400mlTHF and water 30ml, add 10% palladium-charcoal 2g, stirring reaction 2h under the room temperature 5MPa hydrogen pressure, filtering palladium charcoal adds THF150ml in the filtrate, water layer is collected in layering.In THF, add 5% magnesium chloride brine 20ml again, leave standstill, divide water-yielding stratum, repetitive operation 1 time.Water merges, and 0 ℃ slowly splashes into methyl alcohol 30ml, and-10 ℃ are stirred 1h, filters, and the filter cake recrystallization gets target product 2.6g, yield: 49.6%.
Molecular formula: C
21H
27N
5O
7S
2
Molecular weight: 525.6
Ultimate analysis:
Measured value: C, 47.75%; H, 5.34%; N, 13.18%; S, 12.03%
Theoretical value: C, 47.99%; H, 5.18%; N, 13.32%; S, 12.20%
Embodiment 17 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (3-carboxyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl
-6-[(1R)-the 1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid (compound 2)
Concrete preparation method's reference example 16.Throw (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl (3-carboxyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 7.3g (10mmol).Get target product 2.0g, yield: 41.3%.
Molecular formula: C
22H
26N
4O
7S
Molecular weight: 490.53
Ultimate analysis:
Measured value: C, 53.53%; H, 5.65%; N, 11.31%; S, 6.30%
Theoretical value: C, 53.87%; H, 5.34%; N, 11.42%; S, 6.54%
Embodiment 18 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl
-6-[(1R)-the 1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid (compound 3)
Concrete preparation method's reference example 16.Throw (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 7.5g (10mmol).Get target product 2.6g, yield: 51.2%.
Molecular formula: C
22H
25F
3N
4O
5S
Molecular weight: 514.52
Ultimate analysis:
Measured value: C, 51.16%; H, 5.23%; F, 11.01; N, 10.63%; S, 6.09%
Theoretical value: C, 51.36%; H, 4.90%; F, 11.08; N, 10.89%; S, 6.23%
Embodiment 19 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulphur
Base-6-[(1R)-1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid (compound 4)
Concrete preparation method's reference example 16.Throw (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 7.8g (10mmol).Get target product 2.5g, yield: 45.5%.
Molecular formula: C
22H
24ClF
3N
4O
5S
Molecular weight: 548.96
Ultimate analysis:
Measured value: C, 48.26%; H, 4.66%; Cl, 6.35%; F, 10.51%; N, 10.37%; S, 5.57%
Theoretical value: C, 48.13%; H, 4.41%; Cl, 6.46%; F, 10.38%; N, 10.21%; S, 5.84%
Embodiment 20 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-tetramethyleneimine-4-yl] sulfenyl
-6-[(1R)-the 1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid (compound 7)
Concrete preparation method's reference example 16.Throw (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-1-(tertbutyloxycarbonyl) tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 7.4g (10mmol).Get target product 2.5g, yield: 48.9%.
Molecular formula: C
22H
25N
5O
5S
2
Molecular weight: 503.59
Ultimate analysis:
Measured value: C, 52.20%; H, 5.34%; N, 13.74%; S, 12.56%
Theoretical value: C, 52.47%; H, 5.00%; N, 13.91%; S, 12.73%
Embodiment 21 (2S, 4S)-4-acetylthio-2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-N-is to nitro carbobenzoxy-(Cbz)-pyrrole
Cough up the preparation of alkane
In the exsiccant reaction flask, add (2S, 4S)-4-acetylthio-2-carboxy-N-to nitro carbobenzoxy-(Cbz)-tetramethyleneimine 11.1g (30mmol), anhydrous tetrahydro furan 100ml.Under nitrogen protection, add DCC (dicyclohexyl carbimide) 7.0g (45mmol) in room temperature, reaction 0.5h is adding 6.1g (35mmol) 3-difluoro-methoxy phenylhydrazine in batches below 10 ℃, continue reaction 0.5h.With hydrochloric acid soln, water, the saturated nacl aqueous solution washing of 1N, concentrating under reduced pressure, solid get solid 12.4g, yield: 78.7% with methyl alcohol-ethyl acetate solution recrystallization to organic phase successively.
Embodiment 22 (2S, 4S)-4-acetylthio-2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]-N-is to nitro carbobenzoxy-(Cbz)-pyrrole
Cough up the preparation of alkane
Preparation method's reference example 1, throw (2S, 4S)-4-acetylthio-2-carboxyl N-is to nitro carbobenzoxy-(Cbz)-tetramethyleneimine 11.1g (30mmol), DCC (dicyclohexyl carbimide) 9.3g (45mmol), 6.7g (35mmol) 3-trifluoromethoxy phenylhydrazine.Get solid 13.0g, yield: 79.6%.
Embodiment 23 (2S, 4S)-4-sulfydryl-2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-N-is to nitro carbobenzoxy-(Cbz)-pyrroles
The preparation of alkane
In reaction flask, add (2S, 4S)-4-acetylthio-2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl] N-is to nitro carbobenzoxy-(Cbz)-tetramethyleneimine 26.2g (50mmol), 10% hydrochloric acid-methanol solution 100ml, temperature rising reflux stirring reaction 1.5h.Frozen water cooling adds 100ml water down, divides water-yielding stratum, and water layer is used the dichloromethane extraction of 50ml * 3 again, merges organic layer, anhydrous sodium sulfate drying, is concentrated into driedly, is adjusted to neutrality with dilute alkaline soln, separates out solid, product 22.2g, yield: 92.2%.
Embodiment 24 (2S, 4S)-4-sulfydryl-2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]-N-is to nitro carbobenzoxy-(Cbz)-tetramethyleneimine
Preparation
With reference to embodiment 3 preparation methods, throw (2S, 4S)-4-acetylthio-2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]-N-is to nitro carbobenzoxy-(Cbz)-tetramethyleneimine 27.1g (50mmol).Get product: 23.3g, yield: 93.1%.
Embodiment 25 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-N-is to the nitro carbobenzoxy-(Cbz)
-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid is to nitrobenzyl
The preparation of ester
In the dry reaction bottle, add (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] the acetonitrile 400ml solution of hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 35.8g (60mmol) is chilled to below-20 ℃, add diisopropylethylamine 16ml and (2S, 4S)-and 4-sulfydryl-2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-N-is to the acetonitrile 200ml solution of nitro carbobenzoxy-(Cbz)-tetramethyleneimine 31.4g (65mmol), and 0 ℃ is stirred 24h.After reaction finishes, add ethyl acetate 600ml dilution, water, saturated salt washing successively, organic layer drying, concentrated gets solid 30.3g, yield: 61.0%.
Embodiment 26 (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]-N-is to the nitro carbobenzoxy-(Cbz)
-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid is to nitrobenzyl
The preparation of ester
Concrete preparation method's reference example 5.Throw (4R, 5S, 6S)-3-hexichol oxygen phosphorus acyloxy-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0]-2-alkene-2-carboxy acid mutual-nitro carbobenzoxy 35.8g (60mmol), (2S, 4S)-4-sulfydryl-2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]-N-is to nitro carbobenzoxy-(Cbz)-tetramethyleneimine 32.5g (65mmol).Get product 31.3g, yield: 61.7%.
Embodiment 27 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-tetramethyleneimine-4-yl] sulfenyl
-6-[(1R)-the 1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid (compound 5)
With (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-N-is to nitro carbobenzoxy-(Cbz)-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 24.8g (30mmol) is dissolved in the mixed solution of 600mlTHF and water 50ml, add 10% Lin Dela palladium-charcoal 8g, stirring reaction 2h under the room temperature 5MPa hydrogen pressure, filtering palladium charcoal, remove tetrahydrofuran (THF) under reduced pressure, residual solution with the ethyl acetate washing once.Water layer slowly splashes into ethanol 200ml in 0 ℃, and-10 ℃ are stirred 1h, filter, white crystal 7.3g, yield: 47.6%.
Molecular formula: C
22H
26F
2N
4O
6S
Molecular weight: 512.53
Ultimate analysis:
Measured value: C, 51.25%; H, 5.39%; F, 7.77%; N, 10.69%; S, 6.43%
Theoretical value: C, 51.56%; H, 5.11%; F, 7.41%; N, 10.93%; S, 6.26%
Embodiment 28 (4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]--tetramethyleneimine-4-yl] sulfenyl
-6-[(1R)-the 1-hydroxyethyl]-preparation of 4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid (compound 6)
Concrete preparation method's reference example 7.Throw (4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl] N-is to nitro carbobenzoxy-(Cbz)-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxy acid mutual-nitro carbobenzoxy 25.3g (30mmol).Get target product 7.8g, yield: 48.9%.
Molecular formula: C
22H
25F
3N
4O
6S
Molecular weight: 530.52
Ultimate analysis:
Measured value: C, 49.65%; H, 4.98%; F, 10.55%; N, 10.32%; S, 6.32%
Theoretical value: C, 49.81%; H, 4.75%; F, 10.74%; N, 10.56%; S, 6.04%
The preparation of embodiment 29 The compounds of this invention aseptic powder injections
1, prescription:
Prescription 1:
Any one 250g (in compound) in the compound 1-7 or derivatives thereof
Prepare 1000 altogether
Prescription 2:
Any one 500g (in compound) in the compound 1-7 or derivatives thereof
Prepare 1000 altogether
Prescription 3:
Any one 1000g (in compound) in the compound 1-7 or derivatives thereof
Prepare 1000 altogether
Prescription 4:
Any one 2000g (in compound) in the compound 1-7 or derivatives thereof
Prepare 1000 altogether
2, preparation technology: will prepare used antibiotic glass bottle, plug etc. and carry out aseptically process; Take by weighing raw material (feeding intake after the conversion) by prescription, sterilized powder is placed the portioning machine packing, detect loading amount at any time; Jump a queue, gland, finished product is examined entirely, the packing warehouse-in.
The preparation of embodiment 30 The compounds of this invention tablets
1, prescription:
Prescription 1:
Any one 250g (in compound) in the compound 1-7 or derivatives thereof
Pregelatinized Starch 50g
Low-substituted hydroxypropyl cellulose 40g
Microcrystalline Cellulose 40g
The 2%HPMC aqueous solution is an amount of
Micropowder silica gel 4.0g
Magnesium Stearate 4.0g
Carboxymethylstach sodium 2.0g
Prepare 1000 altogether
Prescription 2:
Any one 125g (in compound) in the compound 1-7 or derivatives thereof
Pregelatinized Starch 50g
Low-substituted hydroxypropyl cellulose 40g
Microcrystalline Cellulose 40g
The 2%HPMC aqueous solution is an amount of
Micropowder silica gel 4.0g
Magnesium Stearate 4.0g
Carboxymethylstach sodium 2.0g
Prepare 1000 altogether
2, preparation technology: raw material pulverizing is crossed 100 mesh sieves, and all the other auxiliary materials are crossed 100 mesh sieves respectively, and are standby; Take by weighing raw material and auxiliary material according to recipe quantity; Hypromellose 2% the aqueous solution made soluble in water is standby; With in the compound 1-7 or derivatives thereof any one, pregelatinized Starch, low-substituted hydroxypropyl cellulose, Microcrystalline Cellulose mix, it is an amount of to add the 2%HPMC aqueous solution, stirs, and makes suitable softwood; Cross 20 mesh sieve system particles; Particle is dried under 60 ℃ condition; Dry good particle adds Magnesium Stearate, micropowder silica gel and carboxymethylstach sodium, crosses the whole grain of 18 mesh sieves, mixes; Sampling, the work in-process chemical examination; According to the definite sheet weight sheet of chemical examination; Finished product is examined entirely, the packing warehouse-in.
Claims (10)
1, the hydrate of the ester of the compound shown in the general formula (I), its pharmacy acceptable salt, its facile hydrolysis, its isomer, its hydrate and ester or salt:
Wherein, R
1Represent hydrogen atom or carboxyl-protecting group;
R
2Represent hydrogen atom or amino protecting group;
R
3Representative is replaced by one or more substituting groups or unsubstituted following group:
Described substituting group is selected from halogen atom, hydroxyl, carboxyl, amino, nitro, cyano group, replaced or unsubstituted sulfonamido by low alkyl group, by halogen atom, hydroxyl, carboxyl, amino, nitro or cyano group replaces or unsubstituted low alkyl group, lower alkoxy;
R
4, R
5, R
6Independently represent hydrogen atom or low alkyl group respectively.
2, the hydrate of the ester of compound as claimed in claim 1, its pharmacy acceptable salt, its facile hydrolysis, its isomer, its hydrate and ester or salt:
Wherein, R
1Represent hydrogen atom or carboxyl-protecting group,
Described carboxyl-protecting group is selected from methyl, ethyl, the tertiary butyl, methoxymethyl, first thiomethyl, benzyloxymethyl, phenacyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R
2Represent hydrogen atom or amino protecting group,
Described amino protecting group is selected from methyl, ethyl, the tertiary butyl, benzyl, formyl radical, ethanoyl, allyloxy carbonyl, phenacyl, tert-butoxycarbonyl, to the nitro benzyloxycarbonyl, to methoxyl group benzyloxy base carbonyl, 3-acetoxyl group propyl group or diazo;
R
3Representative is replaced by one or more substituting groups or unsubstituted following group:
Described substituting group is selected from halogen atom, and carboxyl is replaced or unsubstituted sulfonamido by low alkyl group, by halogen atom, hydroxyl, carboxyl, amino replacement or unsubstituted low alkyl group, lower alkoxy;
R
4, R
5, R
6Independently represent hydrogen atom, methyl, ethyl or propyl group respectively.
3, the hydrate of the ester of compound as claimed in claim 2, its pharmacy acceptable salt, its facile hydrolysis, its isomer, its hydrate and ester or salt:
Wherein, R
1Represent hydrogen atom or carboxyl-protecting group,
Described carboxyl-protecting group is selected from methyl, the tertiary butyl, allyl group, benzyl, to nitrobenzyl, to methoxy-benzyl or diphenyl methyl;
R
2Represent hydrogen atom or amino protecting group,
Described amino protecting group is selected from methyl, the tertiary butyl, formyl radical, allyloxy carbonyl, tertbutyloxycarbonyl, to the nitro benzyloxycarbonyl, to methoxyl group benzyloxy base carbonyl or diazo;
R
3Representative is replaced by one or more substituting groups or unsubstituted following group:
Described substituting group is selected from fluorine atom, chlorine atom, carboxyl, sulfonamido, the low alkyl group, the lower alkoxy that are replaced by halogen atom;
R
4, R
5, R
6Independently represent hydrogen atom or methyl respectively.
4, compound as claimed in claim 3 is selected from:
(4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (3-sulfoamido-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid,
(4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (3-carboxyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid,
(4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (2-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid,
(4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl (2-chloro-5-trifluoromethyl-benzene-1-yl) diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid,
(4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(3-difluoromethoxy phenyl-1-yl) diazanyl]-than coughing up alkane-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid,
(4R, 5S, 6S)-3-[(2S, 4S)-2-formyl [(3-Trifluoromethyl phenyl ether-1-yl) diazanyl]-than coughing up alkane-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid, perhaps
(4R, 5S, 6S)-3-[(2S, 4S)-and 2-formyl [1-(benzo [d] thiazol-2-yl)] diazanyl-tetramethyleneimine-4-yl] sulfenyl-6-[(1R)-the 1-hydroxyethyl]-4-methyl-7-oxygen-1-azabicyclo-[3,2,0] hept-2-ene"-2-carboxylic acid,
And the hydrate of ester, its isomer, its hydrate, its ester or the salt of pharmacy acceptable salt, its facile hydrolysis.
5, each described compound of claim 1～4, its pharmacy acceptable salt is organic acid salt, inorganic acid salt, organic alkali salt or inorganic base salts.
6, each described compound of claim 1～4; the ester of its facile hydrolysis is for being hydrolyzed into the ester of corresponding carboxylic acid in vivo; comprise lower alkane acyloxyalkyl group ester; lower alkoxycarbonyl oxyalkyl ester; the lactone group ester, lower alkoxy methyl ester, lower alkane acyl amino methyl ester; benzyl ester, the cyano methyl ester.
7, the ester and the hydrate of isomer, its hydrate or its ester or salt and the pharmaceutical composition of one or more pharmaceutical carriers and/or thinner that comprise each described compound of claim 1～4, its pharmacy acceptable salt, its facile hydrolysis.
8, pharmaceutical composition as claimed in claim 7 is pharmaceutically acceptable arbitrary formulation.
9, pharmaceutical composition as claimed in claim 7 contains the hydrate 0.05g～5g of the ester of each described compound of claim 1～4, its pharmacy acceptable salt, its facile hydrolysis and isomer, its hydrate or its ester or salt as essential activeconstituents.
10, the hydrate of ester, its isomer, its hydrate or its ester or the salt of each described compound of claim 1～4, its pharmacy acceptable salt, its facile hydrolysis is in the application that is used for preparing the medicine that treats and/or prevents infectious diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101274662A CN101525336B (en) | 2007-06-26 | 2008-06-26 | Carbapenem compound containing substituted formohydrazide group |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710016610.0 | 2007-06-26 | ||
| CN200710016610 | 2007-06-26 | ||
| CN2008101274662A CN101525336B (en) | 2007-06-26 | 2008-06-26 | Carbapenem compound containing substituted formohydrazide group |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101525336A true CN101525336A (en) | 2009-09-09 |
| CN101525336B CN101525336B (en) | 2011-06-15 |
Family
ID=41093431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101274662A Expired - Fee Related CN101525336B (en) | 2007-06-26 | 2008-06-26 | Carbapenem compound containing substituted formohydrazide group |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101525336B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603746A (en) * | 2010-12-28 | 2012-07-25 | 山东轩竹医药科技有限公司 | Carbapenem derivative |
| ES2651943A1 (en) * | 2016-07-29 | 2018-01-30 | ABAC Therapeutics, S.L. | Antibacterial agents of 2-pyrrolidinylphenylhydrazides (Machine-translation by Google Translate, not legally binding) |
-
2008
- 2008-06-26 CN CN2008101274662A patent/CN101525336B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102603746A (en) * | 2010-12-28 | 2012-07-25 | 山东轩竹医药科技有限公司 | Carbapenem derivative |
| CN102603746B (en) * | 2010-12-28 | 2015-07-15 | 山东轩竹医药科技有限公司 | Carbapenem derivative |
| ES2651943A1 (en) * | 2016-07-29 | 2018-01-30 | ABAC Therapeutics, S.L. | Antibacterial agents of 2-pyrrolidinylphenylhydrazides (Machine-translation by Google Translate, not legally binding) |
| WO2018020004A1 (en) | 2016-07-29 | 2018-02-01 | Abac Therapeutics, S.L | 2-pyrrolidine phenylhydrazides antibacterial agents |
| US10919851B2 (en) | 2016-07-29 | 2021-02-16 | ABAC Therapeutics, S.L. | 2-pyrrolidine phenylhydrazides antibacterial agents |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101525336B (en) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101372489B (en) | Carbapenem derivative containing sulfhydryl pyrrolidine formamide benzyl | |
| CN101525336B (en) | Carbapenem compound containing substituted formohydrazide group | |
| CN101333217A (en) | 1-methyl carbapenem antibiotics | |
| CN101367804B (en) | Penem derivant containing adamantane | |
| CN101323615B (en) | Pennem derivates containing formamide heterocycle sulfonic acid amide sulfhydryl pyrrolidine | |
| CN101357918B (en) | Penem derivative containing isothioureido sulfhydryl pyrrolidine | |
| CN101367814B (en) | Sulfhydryl pyrrolidine formyl piperidine substituted penem derivant | |
| CN101357919B (en) | Penem derivative containing sulfhydryl formamide benzenesulfonyl pyrrolidine | |
| CN101367811B (en) | Carbon substituted penems antibiotics | |
| CN101357920B (en) | Penem derivative containing sulfhydryl pyrrolidine formamido triazine | |
| CN101367809B (en) | Penem derivant containing sulfhydryl pyrrolidine formhydrazide | |
| CN101367816B (en) | Carbpenem derivants | |
| CN101328179B (en) | Sulfhydryl pyrrolidine penem derivates containing oxo aza ring | |
| CN101343271B (en) | Penem derivant containing isoxazole alkyl ketone | |
| CN101367817B (en) | Carbpenem compound containing cyclohexenone formamido group | |
| CN101367807B (en) | Sulfhydryl pyrrolidine formamido pyridine substituted penem derivant | |
| CN101328178B (en) | Penem derivates containing thiophen substituted sulfhydryl pyrrolidine | |
| CN101367812B (en) | Sulfhydryl pyrrolidine formamido cyclopentene acid substituted penem derivant | |
| CN101367805B (en) | Formyl guanidino substituted sulfhydryl pyrrolidine carbpenem compounds | |
| CN101343272B (en) | Carbpenem compound containing cyclohexane | |
| CN101372488A (en) | Novel carbapenem compound | |
| CN101362759B (en) | Dihydropyrrole methano substituted carbapenem derivates | |
| CN101367810A (en) | Novel carbpenem antibiotic | |
| CN101333219B (en) | Penem derivates with mercapto pyrrolidine formamide benzene alkyl heterocycle | |
| CN101260108B (en) | Mercaptopyrrolidone carbon penems derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110615 Termination date: 20120626 |